Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

    Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced an agreement with Psychedelics Today, LLC ("Psychedelics Today'') to help drive brand awareness of the Company's Psychedelics Genetic Test Kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen").The agreement with...

    2022-01-18 8:30 AM EST
  • Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

    Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announced that it has filed a preliminary short form base shelf prospectus dated January 14, 2022 (the "Preliminary Prospectus") with the securities commissions in each of the provinces and territories of Canada.The Preliminary Prospectus has not yet become final for the purpose of the sale of securities. Once the receipts for the final short form base shelf prospectus...

    2022-01-18 8:00 AM EST
  • Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

    Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced the submission of the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the Assessment of Ethics of Biomedical Research (the "Ethics Committee"). The...

    2022-01-06 8:30 AM EST
  • Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

    Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), is now available for sale in Canada and the United States.HaluGen's Psychedelics Genetic Test Kit...

    2021-12-21 8:30 AM EST
  • Entheon Biomedical Announces EEG Patent Application & Provides Research Update

    Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as well as nonclinical and clinical programs. US Provisional Patent Filed In furtherance of its program, the Company filed US Provisional Patent Application No. 63/283,051, titled...

    2021-12-16 8:30 AM EST
  • Entheon to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

    Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that Timothy Ko, Entheon's Chief Executive Officer, will be presenting at the 2nd Annual H.C. Wainwright Psychedelics Conference being held virtually on Monday, December 6, 2021.Mr. Ko's presentation will be available on...

    2021-12-03 7:16 PM EST
  • Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - December 1, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that Dr. Henry Kranzler, Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine, has been appointed to Entheon's Advisory Board.Dr....

    2021-12-01 8:30 AM EST
  • Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its upcoming human trial, EBRX-101 and on nonclinical DMT initiatives.Clinical Trial UpdateThe Company announces today that GMP DMT drug product has shipped from Ofichem Laboratorium to CHDR's partner pharmacy. Formulation and stability testing of the DMT drug product by CHDR's...

    2021-11-24 8:00 AM EST